إسرائيل - العربية - Ministry of Health

teva pharmaceutical indust.ltd - atenolol 100 mg - tablets - atenolol - management of angina pectoris and hypertension,including hypertension of renal origin. late intervention after acute myocardial infarction.

إسرائيل - العربية - Ministry of Health

teva pharmaceutical indust.ltd - clotrimazole 1 %; dexamethasone acetate 0.044 % - cream - dexamethasone - tevacutan is indicated for the treatment of mycotic infections of the skin complicated by inflammation and/or secondary infection.

إسرائيل - العربية - Ministry of Health

abic ltd. - ofloxacin 200 mg - tablets - ofloxacin - bacterial infections due to ofloxacin-susceptible microorganisms, such as:- acute, chronic, or recurrent lower respiratory tract infections (bronchitis) pneumonia (not for the treatment of first choice in pnemonia caused by pneumococci). - chronic and recurrent infections of the ear, nose, and throat. ofloxacin is in general not indicated for the treatment of acute tonsillitis caused by betahaemolytic streptococci. - infections of soft tissues and skin. - infections of the bones and joints. - abdominal infections including infections in the pelvis minor and bacterial enteritis. - infections of the kidney, urinary tract, and genital organs, gonorrhoea.prevention of infections due to ofloxacin-susceptible pathogens in patients with a significant reduction in resistance to infections (e.g. in neutropenic state).

إسرائيل - العربية - Ministry of Health

teva pharmaceutical indust.ltd - mirtazapine 30 mg - tablets - mirtazapine - episode of major depression.

إسرائيل - العربية - Ministry of Health

teva pharmaceutical indust.ltd - bicalutamide 50 mg - tablets - bicalutamide - for the treatment of advanced prostate cancer in combination with lhrh analog therapy or surgical castration.

إسرائيل - العربية - Ministry of Health

teva pharmaceutical indust.ltd - bicalutamide 150 mg - tablets - bicalutamide - in patients with locally advanced prostate cancer (t3-t4 any n m0 t1-t2 n+ m0) bicalutamide is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.